Core Points - The company guarantees the authenticity, accuracy, and completeness of the quarterly report, with all board members and senior management assuming legal responsibility for its content [2][3]. Financial Data - The financial report for the third quarter is not audited [3]. - The company’s net capital and risk control indicators continue to comply with the relevant regulations set by the China Securities Regulatory Commission [4]. - Non-recurring gains and losses are applicable, with specific projects identified as significant [4]. Shareholder Information - There were no new litigation or arbitration cases involving amounts exceeding 50 million yuan during the reporting period [7]. - The company is involved in an ongoing appeal regarding a financing dispute with Southwest Synthetic Pharmaceutical Group, with the first-instance judgment requiring the company to receive over 178 million yuan in principal and interest [7]. Stock Issuance and Buyback - The company has received approval for a stock issuance to specific investors and will proceed according to legal requirements [8]. - The company completed a share buyback of 46,962,500 shares, representing 0.67% of the total share capital, at a total cost of approximately 300 million yuan [8]. Branch Changes - During the reporting period, the company did not establish new branches but relocated six securities business departments and closed seven [9].